Myeloma bone disease is due to interactions of myeloma cells with the bone marrow
microenvironment, and is associated with pathologic fractures, neurologic symptoms and …

OBJECTIVE: To evaluate bone metabolism in patients with ankylosing spondylitis (AS) and
test the hypothesis that osteoprotegerin (OPG) serum concentrations are correlated with the …

Myelodysplastic syndromes (MDSs) represent clonal disorders mainly of the elderly that are
characterized by ineffective hematopoiesis and an increased risk of transformation into …

Sclerostin, which is primarily produced by the osteocytes, inhibits the canonical Wnt pathway
and thereby the osteoblasts and stimulates RANKL release by the osteocytes and thereby …

This retrospective database study assessed 2-year persistence with bisphosphonates or
denosumab in a large German cohort of women with a first-time prescription for osteoporosis …

With improved outcome of allogeneic stem cell transplantation (allo‐SCT) for hematologic
malignancies, long‐term complications gain greater importance. Skeletal complications such …

Osteoprotegerin (OPG) regulates osteoclast and immune functions and appears to
represent a protective factor for the vascular system. However, the role of OPG in human …

objective Osteoprotegerin (OPG) represents a secreted cytokine which regulates bone mass
by blocking receptor activator of nuclear factor‐κB ligand (RANKL), the principal regulator of …

Purpose: Increased bone resorption is a hallmark of multiple myeloma and is attributable to
osteoclast activation. Recent studies showed that the receptor activator of nuclear factor κB …

Context Denosumab discontinuation is characterized by an increase in bone turnover
overriding pretreatment status, a rapid bone loss in the majority and multiple vertebral fractures (…